Stockscreener 앱 받기
7.20
4.00%
-0.30
전일 마감가:
$7.50
열려 있는:
$7.5
하루 거래량:
2.03M
Relative Volume:
0.70
시가총액:
$525.53M
수익:
$161.10M
순이익/손실:
$-308.60M
주가수익비율:
-1.5418
EPS:
-4.67
순현금흐름:
$-259.90M
1주 성능:
+10.60%
1개월 성능:
-23.16%
6개월 성능:
-73.05%
1년 성능:
-77.67%
1일 변동 폭
$6.95
$7.50
1주일 범위
$6.48
$7.60
52주 변동 폭
$5.90
$34.11
Arvinas Inc Stock (ARVN) Company Profile
명칭
Arvinas Inc
전화
203-535-1456
주소
395 WINCHESTER AVE, NEW HAVEN, CT
ARVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.20 | 475.17M | 161.10M | -308.60M | -259.90M | -4.67 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-05-02 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-03-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-12 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-03-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2024-02-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-01 | 개시 | Goldman | Buy |
| 2023-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-11-20 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-10-23 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-01-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-01-03 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 개시 | Barclays | Overweight |
| 2022-06-21 | 개시 | Jefferies | Hold |
| 2022-05-09 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-04-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Overweight |
| 2022-01-19 | 개시 | Goldman | Buy |
| 2021-12-07 | 개시 | Cowen | Outperform |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-09-30 | 개시 | Stifel | Buy |
| 2021-09-09 | 개시 | BofA Securities | Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-04-21 | 개시 | Truist | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-12-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-06-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Oppenheimer | Perform |
| 2019-12-19 | 개시 | H.C. Wainwright | Buy |
| 2019-11-25 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-25 | 개시 | Wedbush | Outperform |
| 2019-09-12 | 개시 | BMO Capital Markets | Outperform |
| 2019-08-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-22 | 개시 | Citigroup | Buy |
| 2018-10-22 | 개시 | Goldman | Neutral |
| 2018-10-22 | 개시 | Piper Jaffray | Overweight |
모두보기
Arvinas Inc 주식(ARVN)의 최신 뉴스
Does Arvinas (ARVN) Have the Potential to Rally 94.93% as Wall Street Analysts Expect? - Yahoo Finance
Arvinas to Present at Jefferies Global Healthcare Conference | ARVN Stock News - GuruFocus
Protein Degradation Pioneer Arvinas Reveals Latest Progress at Major Jefferies Healthcare Conference - Stock Titan
Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Arvinas, Inc. (NASDAQ:ARVN) Shares Purchased by Two Sigma Advisers LP - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arvinas (NASDAQ:ARVN) Trading 7.9% HigherWhat's Next? - MarketBeat
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm - Yahoo Finance
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Arvinas, Inc. (ARVN) - Business Wire
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks By Investing.com - Investing.com South Africa
Woodline Partners LP Boosts Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas’s SWOT analysis: stock outlook shifts amid clinical setbacks - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, Inc.ARVN - Kilgore News Herald
Twinbeech Capital LP Acquires New Stake in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Buys 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, - GlobeNewswire
BNP Paribas Financial Markets Purchases 7,243 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Bragar Eagel & Squire, P.C. Is Investigating Organon, Landstar, Arvinas, and GoHealth and ... - Bluefield Daily Telegraph
RTW Investments LP Raises Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
(ARVN) Proactive Strategies - news.stocktradersdaily.com
Patient Square Capital LP Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Northern Trust Corp Purchases 42,638 Shares of Arvinas, Inc. (NASDAQ:ARVN) - Defense World
UBS Group Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - Defense World
Arvinas (ARVN) Price Target Slashed by UBS but Rating Maintained | ARVN Stock News - GuruFocus
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating - marketscreener.com
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | - GuruFocus
Arvinas (ARVN) Faces Price Target Reduction Amid Trial Changes | ARVN Stock News - GuruFocus
Dimensional Fund Advisors LP Acquires 186,254 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Cantor Fitzgerald Lifts Earnings Estimates for Arvinas - MarketBeat
ATTENTION ARVN SHAREHOLDERS: Investors Who Lost Money on Arvinas, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arvinas, ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Are Investors Declined To Sell Their Arvinas Inc (NASDAQ: ARVN) Holdings? - Stocksregister
Algert Global LLC Increases Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Did Arvinas, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateARVN - ACCESS Newswire
An Investigation Has Commenced on Behalf of Arvinas, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your ARVN Losses. - ACCESS Newswire
Morgan Stanley Lowers Arvinas (NASDAQ:ARVN) Price Target to $11.00 - Defense World
Arvinas (NASDAQ:ARVN) Receives "Hold" Rating from Truist Financial - MarketBeat
BMO Capital Markets Issues Pessimistic Forecast for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
(ARVN) Investment Analysis - news.stocktradersdaily.com
Arvinas, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsARVN - ACCESS Newswire
Morgan Stanley Adjusts Price Target for Arvinas (ARVN) | ARVN Stock News - GuruFocus
Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Dimensional Fund Advisors LP Raises Position in Arvinas, Inc. (NASDAQ:ARVN) - Defense World
Short Interest in Arvinas, Inc. (NASDAQ:ARVN) Expands By 21.0% - MarketBeat
FY2025 EPS Estimates for Arvinas Lifted by Cantor Fitzgerald - Defense World
ArrowMark Colorado Holdings LLC Buys 532,105 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Levi & Korsinsky Announces an Investigation on Behalf of Arvinas, Inc. (ARVN) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
ARVINAS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Arvinas (NASDAQ:ARVN) Posts Earnings Results - MarketBeat
Arvinas Inc (ARVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):